37
| 1 | 2012
Klinisk Biokemi i Norden
7.
Kronenberg F, Trenkwalder E, Dieplinger H,
Utermann G. Lipoprotein(a) in stored plasma
samples and the ravages of time: why epidemio-
logical studies might fail. Arterioscler Thromb
Vasc Biol 1996;16:1568-72.
8.
Danesh J, Collins R, Peto R. Lipoprotein(a) and
coronary heart disease - Meta-analysis of pro-
spective studies. Circulation 2000;102:1082-5.
9.
Ariyo AA, Thach C, Tracy R. Lp(a) lipoprotein,
vascular disease, and mortality in the elderly. N
Engl J Med 2003;349:2108-15.
10.
Rifai N, Ma J, Sacks FM et al. Apolipoprotein(a)
size and lipoprotein(a) concentration and future
risk of angina pectoris with evidence of severe
coronary atherosclerosis in men: The Physi-
cians’ Health Study. Clin Chem 2004;50:1364-
71.
11.
Danik JS, Rifai N, Buring JE, Ridker PM.
Lipoprotein(a), measured with an assay inde-
pendent of apolipoprotein(a) isoform size, and
risk of future cardiovascular events among ini-
tially healthy women. JAMA 2006;296:1363-70.
12.
Kamstrup PR, Benn M, Tybjærg-Hansen A,
Nordestgaard BG. Extreme lipoprotein(a) levels
and risk of myocardial infarction in the general
population: the Copenhagen City Heart Study.
Circulation 2008;117:176-84.
13.
Kamstrup PR, Tybjærg-Hansen A, Steffen-
sen R, Nordestgaard BG. Genetically elevated
lipoprotein(a) and increased risk of myocardial
infarction. JAMA 2009;301:2331-9.
14.
Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a)
concentration and the risk of coronary heart dis-
ease, stroke, and nonvascular mortality. JAMA
2009;302:412-23.
15.
Clarke R, Peden JF, Hopewell JC et al. Genetic
variants associated with Lp(a) lipoprotein
level and coronary disease. N Engl J Med
2009;361:2518-28.
16.
Boffa MB, Marcovina SM, Koschinsky ML.
Lipoprotein(a) as a risk factor for atherosclero-
sis and thrombosis: mechanistic insights from
animal models. Clin Biochem 2004;37:333-43.
17.
Deb A, Caplice NM. Lipoprotein(a): new
insights into mechanisms of atherogenesis and
thrombosis. Clin Cardiol 2004;27:258-64.
18.
Graham I, Atar D, Borch-Johnsen K et al.
European guidelines on cardiovascular disease
prevention in clinical practice: executive sum-
mary: Fourth Joint Task Force of the European
Society of Cardiology and Other Societies on
Cardiovascular Disease Prevention in Clinical
Practice (Constituted by representatives of nine
societies and by invited experts). Eur Heart J
2007;28:2375-414.
19.
Grundy SM, Cleeman JI, Merz CN et al. Impli-
cations of recent clinical trials for the National
Cholesterol Education Program Adult Treat-
ment Panel III guidelines. Arterioscler Thromb
Vasc Biol 2004;24:e149-e161.
20.
Nordestgaard BG, Chapman MJ, Ray K et al.
Lipoprotein(a) as a cardiovascular risk factor:
current status. Eur Heart J 2010;31:2844-53.
21.
Tate JR, Rifai N, Berg K et al. International Fed-
eration of Clinical Chemistry standardization
project for the measurement of lipoprotein(a).
Phase I. Evaluation of the analytical perfor-
mance of lipoprotein(a) assay systems and com-
mercial calibrators. Clin Chem 1998;44:1629-40.
22.
Tate JR, Berg K, Couderc R et al. International
Federation of Clinical Chemistry and Labora-
tory Medicine (IFCC) Standardization Project
for the Measurement of Lipoprotein(a). Phase 2:
selection and properties of a proposed second-
ary reference material for lipoprotein(a). Clin
Chem Lab Med 1999;37:949-58.
23.
Marcovina SM, Albers JJ, Scanu AM et al.
Use of a reference material proposed by the
International Federation of Clinical Chemistry
and Laboratory Medicine to evaluate analyti-
cal methods for the determination of plasma
lipoprotein(a). Clin Chem 2000;46:1956-67.
24.
Marcovina SM, Koschinsky ML, Albers JJ, Skar-
latos S. Report of the National Heart, Lung, and
Blood Institute Workshop on Lipoprotein(a)
and Cardiovascular Disease: recent advances
and future directions. Clin Chem 2003;49:1785-
96.
25.
Dati F, Tate JR, Marcovina SM, Steinmetz A.
First WHO/IFCC International Reference Rea-
gent for Lipoprotein(a) for Immunoassay--Lp(a)
SRM 2B. Clin Chem Lab Med 2004;42:670-6.
